CE2 - COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY VERSUS A DUAL INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

Cost Effectiveness ◽

Triple Therapy ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Cost-Effectiveness of a Single Inhaler Triple Therapy vs a Dual Inhaled Corticosteroid Plus Long-Acting Beta Agonist (ICS/LABA) for Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom (UK)

Value in Health ◽

10.1016/j.jval.2018.04.1590 ◽

2018 ◽

Vol 21 ◽

pp. S234

Author(s):

E Fenwick ◽

AA Martin ◽

M Schroeder ◽

D Vetrini ◽

S Mealing ◽

...

Keyword(s):

United Kingdom ◽

Cost Effectiveness ◽

Triple Therapy ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

The United Kingdom ◽

Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review

Expert Review of Respiratory Medicine ◽

10.1080/17476348.2019.1665514 ◽

2019 ◽

Vol 13 (11) ◽

pp. 1087-1094 ◽

Cited By ~ 1

Author(s):

Paolo Solidoro ◽

Filippo Patrucco ◽

Diego Bagnasco

Keyword(s):

Pulmonary Disease ◽

Fixed Combination ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease

Cureus ◽

10.7759/cureus.19168 ◽

2021 ◽

Author(s):

Mizuki Yuasa ◽

Yosuke Tanaka ◽

Tohru Tanaka ◽

Takeru Kashiwada ◽

Namiko Taniuchi ◽

...

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Agonist Therapy ◽

Muscarinic Antagonist ◽

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd012066.pub2 ◽

2017 ◽

Cited By ~ 18

Author(s):

Nobuyuki Horita ◽

Atsushi Goto ◽

Yuji Shibata ◽

Erika Ota ◽

Kentaro Nakashima ◽

...

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary disease

10.1002/14651858.cd012066 ◽

2016 ◽

Cited By ~ 2

Author(s):

Nobuyuki Horita ◽

Atsushi Goto ◽

Erika Ota ◽

Kentaro Nakashima ◽

Kenjiro Nagai ◽

...

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Clinical And Economic Burden Of Asthma And Chronic Obstructive Pulmonary Disease In The Uk: Impact Of Critical Inhaler Errors With Inhaled Corticosteroid + Long-Acting Beta Agonist Fixed-Dose Combinations

Value in Health ◽

10.1016/j.jval.2014.03.1016 ◽

2014 ◽

Vol 17 (3) ◽

pp. A174 ◽

Cited By ~ 2

Author(s):

A. Lewis ◽

M. Blackney ◽

S. Torvinen ◽

A. Plich

Keyword(s):

Pulmonary Disease ◽

Economic Burden ◽

Beta Agonist ◽

Fixed Dose ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Long Acting ◽

The Uk

Switching from long‐acting beta‐agonist and inhaled corticosteroid to long‐acting beta‐agonist and long‐acting muscarinic antagonist for chronic obstructive pulmonary disease: a case report of inhaled corticosteroid withdrawal

Internal Medicine Journal ◽

10.1111/imj.14931 ◽

2020 ◽

Vol 50 (S3) ◽

pp. 15-18

Author(s):

Jamie Chung Mei Lam

Keyword(s):

Case Report ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Corticosteroid Withdrawal ◽

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal

Applied Health Economics and Health Policy ◽

10.1007/s40258-016-0256-z ◽

2016 ◽

Vol 14 (5) ◽

pp. 579-594 ◽

Cited By ~ 7

Author(s):

M. Reza Maleki-Yazdi ◽

Mathieu Molimard ◽

Dorothy L. Keininger ◽

Jean-Bernard Gruenberger ◽

Joao Carrasco ◽

...

Keyword(s):

Cost Effectiveness ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Adrenergic Agonist ◽

Muscarinic Antagonist ◽

In people with chronic obstructive pulmonary disease, how does combined corticosteroid and long-acting beta-agonist in one inhaler compare with inhaled corticosteroid monotherapy at improving outcomes?

Cochrane Clinical Answers ◽

10.1002/cca.8 ◽

2012 ◽

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

How does long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?

Cochrane Clinical Answers ◽

10.1002/cca.1708 ◽

2017 ◽

Author(s):

Adarsh Gupta

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽